Chinese expert consensus on intranasal anticholinergics for allergic rhinitis

Area of Science:

• Allergy and Rhinology
• Pharmacology
• Immunology

Background:

• Allergic rhinitis (AR) is a common nasal inflammation causing rhinorrhea, congestion, sneezing, and itching.
• Rhinorrhea and nasal congestion are primary AR complaints impacting quality of life.
• Intranasal anticholinergics are guideline-recommended add-on therapies for AR rhinorrhea control.

Purpose of the Study:

• To review the role of acetylcholine and muscarinic receptors in AR pathogenesis.
• To analyze clinical trial findings on intranasal anticholinergics for AR management.
• To provide expert recommendations for precise intranasal anticholinergic use in AR.

Main Methods:

• Systematic review of literature on acetylcholine, muscarinic receptors, and AR.
• Analysis of clinical trial data for intranasal anticholinergics in AR.
• Consensus-based expert recommendations development.

Main Results:

• Acetylcholine and M receptors play a significant role in AR pathophysiology.
• Bencycloquidium bromide, an M1/M3 antagonist, reduces mucus secretion and type 2 inflammation.
• Intranasal anticholinergics demonstrate efficacy in alleviating overall AR nasal symptoms.

Conclusions:

• Intranasal anticholinergics are valuable for managing AR, especially rhinorrhea.
• Bencycloquidium bromide offers a targeted approach to AR symptom control.
• Standardized and precise use of these agents is crucial for optimal patient outcomes.